Area of research
Hematology · Genetics
Research interest
Research interests include Acute Myeloid Leukemia Research, Myeloproliferative Neoplasms: Diagnosis and Treatment, Hematopoietic Stem Cell Transplantation, and Chronic Myeloid Leukemia Treatments.
DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study.
Long-Term Follow-Up of the Baltimore Experience with Hematopoietic Cell Transplantation for Severe Aplastic Anemia Using Post-Transplantation Cyclophosphamide
Personalized Desensitization for Donor-Specific Anti-HLA Antibodies in Allogeneic Blood or Marrow Transplantation.
Chemotherapy regimens with second generation tyrosine kinase inhibitors for <i>BCR-ABL</i> B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation.
Modeling the evolutionary dynamics of clonal hematopoiesis.
Artificial intelligence-driven virtual tumor board enhances precision care in myelodysplastic syndromes
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement
Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with <i>TP53</i> mutant MDS/AML
Imetelstat: a new addition to the therapeutic landscape of lower-risk MDS.
Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms
Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML.
Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbidities.
A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML
ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes
Modified Delphi panel consensus recommendations for management of severe aplastic anemia
International Society for Cell & Gene Therapy Stem Cell Engineering Committee report on the current state of hematopoietic stem and progenitor cell–based genomic therapies and the challenges faced
Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes—Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])
Advancing drug development in myelodysplastic syndromes
Favorable outcomes in MDS and oligoblastic AML-MR after reduced-intensity conditioning allogeneic bone marrow transplantation with post-transplantation cyclophosphamide.
Therapy-related myelodysplastic syndromes and acute myeloid leukemia.
Graft Failure Incidence, Risk Factors, and Outcomes in Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes.
Correlation between peripheral blood and bone marrow mutations among patients with MDS from the National MDS Study
A way to "mimic" the pathophysiology of acquired SAA.
Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes
Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
Extracorporeal membrane oxygenation in adults receiving haematopoietic cell transplantation: an international expert statement